Literature DB >> 29229637

Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model.

Yu-Wei Lin1, Qi Tony Zhou2, Mei-Ling Han3, Ke Chen3, Nikolas J Onufrak4, Jiping Wang3, John D Turnidge5, Benjamin P Howden6,7, Alan Forrest4, Hak-Kim Chan8, Jian Li9.   

Abstract

The pharmacokinetics/pharmacodynamics (PK/PD) of aerosolized colistin was investigated against Acinetobacter baumannii and Klebsiella pneumoniae over 24 h in a neutropenic mouse lung infection model. Dose fractionation studies were performed over 2.64 to 23.8 mg/kg/day, and the data were fitted to a sigmoid inhibitory model. The area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC) in the epithelial lining fluid was the most predictive PK/PD index for aerosolized colistin against both pathogens. Our study provides important pharmacological information for optimizing aerosolized colistin.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter baumannii; Gram-negative bacteria; Klebsiella pneumoniae; polymyxin; pulmonary administration; respiratory tract infections

Mesh:

Substances:

Year:  2018        PMID: 29229637      PMCID: PMC5786800          DOI: 10.1128/AAC.01790-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections.

Authors:  Joseph L Kuti; Christine Ong; Mathew Lo; David Melnick; Norberto Soto; David P Nicolau
Journal:  Int J Antimicrob Agents       Date:  2006-06-06       Impact factor: 5.283

2.  Effect of pulmonary surfactant on antimicrobial activity in vitro.

Authors:  R Schwameis; Z Erdogan-Yildirim; M Manafi; M A Zeitlinger; S Strommer; R Sauermann
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

3.  Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys.

Authors:  Sandrine Marchand; Salim Bouchene; Michèle de Monte; Laurent Guilleminault; Jérôme Montharu; Maria Cabrera; Nicolas Grégoire; Patrice Gobin; Patrice Diot; William Couet; Laurent Vecellio
Journal:  Pharm Res       Date:  2015-06-04       Impact factor: 4.200

4.  Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin.

Authors:  Aline Vidal Lacerda Gontijo; Nicolas Grégoire; Isabelle Lamarche; Patrice Gobin; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

5.  Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients.

Authors:  Matthieu Boisson; Nicolas Grégoire; Marielle Cormier; Patrice Gobin; Sandrine Marchand; William Couet; Olivier Mimoz
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

6.  Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis.

Authors:  Matthew E Falagas; Georgia Sideri; Ioanna P Korbila; Evridiki K Vouloumanou; John H Papadatos; Dimitris A Kafetzis
Journal:  Pediatr Pulmonol       Date:  2010-11

7.  Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Soon-Ee Cheah; Jinxin Zhao; Ke Chen; Jiping Wang; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Unravelling of a mechanism of resistance to colistin in Klebsiella pneumoniae using atomic force microscopy.

Authors:  C Formosa; M Herold; C Vidaillac; R E Duval; E Dague
Journal:  J Antimicrob Chemother       Date:  2015-05-27       Impact factor: 5.790

9.  Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.

Authors:  Kazuro Ikawa; Norifumi Morikawa; Hiroki Ohge; Kayo Ikeda; Taijiro Sueda; Masafumi Taniwaki; Kaoru Kurisu
Journal:  J Infect Chemother       Date:  2010-02       Impact factor: 2.211

10.  Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa.

Authors:  Peter K Linden; Shimon Kusne; Kim Coley; Paulo Fontes; David J Kramer; David Paterson
Journal:  Clin Infect Dis       Date:  2003-10-29       Impact factor: 9.079

View more
  8 in total

1.  Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.

Authors:  Shihui Yu; Xiaohui Pu; Maizbha Uddin Ahmed; Heidi H Yu; Tarun Tejasvi Mutukuri; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-10-06       Impact factor: 5.875

Review 2.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

3.  Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation.

Authors:  Sharad Mangal; Heejun Park; Lingfei Zeng; Heidi H Yu; Yu-Wei Lin; Tony Velkov; John A Denman; Dmitry Zemlyanov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-07-03       Impact factor: 5.875

4.  Surface Composition and Aerosolization Stability of an Inhalable Combinational Powder Formulation Spray Dried Using a Three-Fluid Nozzle.

Authors:  Nivedita Shetty; Yiwen Zhang; Heejun Park; Dmitry Zemlyanov; Dishan Shah; Athena He; Patricia Ahn; Tarun Tejasvi Mutukuri; Hak-Kim Chan; Qi Tony Zhou
Journal:  Pharm Res       Date:  2020-10-09       Impact factor: 4.200

5.  Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance.

Authors:  Chune Zhu; Jianting Chen; Shihui Yu; Chailu Que; Lynne S Taylor; Wen Tan; Chuanbin Wu; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2020-07-24       Impact factor: 4.939

6.  In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.

Authors:  Jianting Chen; Maizbha U Ahmed; Chune Zhu; Shihui Yu; Weisan Pan; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-01-21       Impact factor: 5.875

7.  PKPD Modeling of the Inoculum Effect of Acinetobacter baumannii on Polymyxin B in vivo.

Authors:  Alexia Chauzy; Grace Akrong; Vincent Aranzana-Climent; Jérémy Moreau; Laure Prouvensier; Hélène Mirfendereski; Julien M Buyck; William Couet; Sandrine Marchand
Journal:  Front Pharmacol       Date:  2022-03-16       Impact factor: 5.810

Review 8.  Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents.

Authors:  Rakel Arrazuria; Bernhard Kerscher; Karen E Huber; Jennifer L Hoover; Carina Vingsbo Lundberg; Jon Ulf Hansen; Sylvie Sordello; Stephane Renard; Vincent Aranzana-Climent; Diarmaid Hughes; Philip Gribbon; Lena E Friberg; Isabelle Bekeredjian-Ding
Journal:  Front Microbiol       Date:  2022-09-08       Impact factor: 6.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.